Goldman Sachs’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-218,946
| Closed | -$4.75M | – | 7079 |
|
|
2017
Q2 | $4.75M | Buy |
218,946
+101,227
| +86% | +$1.84M | ﹤0.01% | 3101 |
|
|
2017
Q1 | $1.65M | Sell |
117,719
-12,236
| -9% | -$200K | ﹤0.01% | 3939 |
|
|
2016
Q4 | $2.44M | Buy |
129,955
+54,260
| +72% | +$922K | ﹤0.01% | 3674 |
|
|
2016
Q3 | $1.25M | Sell |
75,695
-6,827
| -8% | -$101K | ﹤0.01% | 4209 |
|
|
2016
Q2 | $1.11M | Buy |
82,522
+18,525
| +29% | +$270K | ﹤0.01% | 4098 |
|
|
2016
Q1 | $978K | Sell |
63,997
-17,791
| -22% | -$279K | ﹤0.01% | 4093 |
|
|
2015
Q4 | $1.62M | Buy |
81,788
+15,858
| +24% | +$301K | ﹤0.01% | 3821 |
|
|
2015
Q3 | $1.15M | Sell |
65,930
-1,570,648
| -96% | -$32M | ﹤0.01% | 4337 |
|
|
2015
Q2 | $33.1M | Sell |
1,636,578
-1,987
| -0.1% | -$38.3K | 0.01% | 1424 |
|
|
2015
Q1 | $28.8M | Buy |
1,638,565
+1,622,297
| +9,972% | +$27.6M | 0.01% | 1502 |
|
|
2014
Q4 | $265K | Sell |
16,268
-575
| -3% | -$10.6K | ﹤0.01% | 5905 |
|
|
2014
Q3 | $372K | Buy |
16,843
+2,536
| +18% | +$51.9K | ﹤0.01% | 5555 |
|
|
2014
Q2 | $288K | Sell |
14,307
-82,040
| -85% | -$1.39M | ﹤0.01% | 5891 |
|
|
2014
Q1 | $1.79M | Sell |
96,347
-84,411
| -47% | -$1.16M | ﹤0.01% | 4081 |
|
|
2013
Q4 | $1.82M | Buy |
180,758
+44,579
| +33% | +$539K | ﹤0.01% | 4168 |
|
|
2013
Q3 | $1.75M | Buy |
+136,179
| New | +$1.68M | ﹤0.01% | 4040 |
|
Other funds holding AMRI
Goldman Sachs's AMRI Position: Q3 2017 in Review
Goldman Sachs sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 218,946 shares — an estimated $4.75M sold.
Goldman Sachs first reported a position in AMRI in Q3 2013 and held it in 16 quarters. The position peaked at $33.1M in Q2 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Goldman Sachs reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Goldman Sachs sold 218,946 Albany Molecular Research Inc shares in Q3 2017, an estimated $4.75M.
- Goldman Sachs first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 16 quarters.
- Goldman Sachs's Albany Molecular Research Inc position peaked at $33.1M in Q2 2015.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.